Arlington, MA, United States of America

Lisa Kann

USPTO Granted Patents = 2 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2010-2013

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Lisa Kann: Innovator in Molecular Analysis

Introduction

Lisa Kann, an accomplished inventor based in Arlington, MA, has made significant contributions to the field of genetic analysis. With a remarkable portfolio consisting of two patents, she has focused her efforts on methods that enhance the detection of nucleic acid sequence variants, particularly in the context of cancer diagnostics.

Latest Patents

Lisa's innovative work is exemplified in her latest patents, which detail methods and compositions for detecting the presence of nucleic acid sequence variants in a subpopulation of nucleic acid molecules found in biological samples. These methods play a crucial role in identifying individuals with genetic mutations that may indicate a predisposition to cancer. Her dedication to advancing molecular analysis continues to impact the healthcare sector positively.

Career Highlights

Throughout her career, Lisa has held key positions at notable companies in the genetics and biotechnology industries. She has notably worked with Genzyme Corporation and Esoterix Genetic Laboratories, LLC, where her expertise in molecular diagnostics has been instrumental in developing groundbreaking techniques for genetic assessment.

Collaborations

Lisa has had the opportunity to collaborate with esteemed professionals in her field, including her coworkers Anthony P. Shuber and Duncan H. Whitney. These collaborations have not only enriched her research but have also contributed to the collective advancement of methodologies in genetic analysis.

Conclusion

With her innovative contributions to molecular event analysis, Lisa Kann stands out as a key figure in the field of genetic research. Her patents, impactful collaborations, and professional experiences underscore her commitment to developing pioneering solutions that can transform cancer diagnostics and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…